Merck Announces FDA Acceptance of Biologics License Application for Investigational Grass Pollen Allergy Immunotherapy Tablet

Dateline City: 

WHITEHOUSE STATION, N.J.

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the Biologics License Application (BLA) for its
investigational Timothy grass pollen (Phleum pratense) allergy
immunotherapy tablet (AIT) has been accepted for review by the U.S. Food
and Drug Administration (FDA). In March, the company also submitted a
BLA to the FDA for its investigational ragweed pollen (Ambrosia
artemisiifolia) AIT.

Language: 

English

Contact HTML: 

MerckMedia:Pam Eisele, [phone]Tracy Ogden, [phone]orInvestors:Justin Holko, [phone]

Ticker Slug: 

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Research and Development News - March 27, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Source Type: news